Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-08-23
2005-08-23
Raymond, Richard L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S266100, C514S266300, C544S282000, C544S287000, C544S293000
Reexamination Certificate
active
06933300
ABSTRACT:
Inhibitors of JAK3 kinase for the treatment of allergy, and others are described.
REFERENCES:
patent: 3594480 (1971-07-01), Cronin et al.
patent: 4322420 (1982-03-01), Kobayashi et al.
patent: 4343940 (1982-08-01), Kreighbaum et al.
patent: 4559157 (1985-12-01), Smith et al.
patent: 4608392 (1986-08-01), Jacquet et al.
patent: 4820508 (1989-04-01), Wortzman
patent: 4938949 (1990-07-01), Borch et al.
patent: 4992478 (1991-02-01), Geria
patent: 5817674 (1998-10-01), Clemence et al.
patent: 5916792 (1999-06-01), Civin et al.
patent: 6080747 (2000-06-01), Uckun et al.
patent: 6080748 (2000-06-01), Uckun et al.
patent: 6313130 (2001-11-01), Uckun et al.
patent: 6326373 (2001-12-01), Uckun et al.
patent: 0 607 439 (1994-07-01), None
patent: WO 95/15758 (1995-06-01), None
patent: WO 00/10981 (2000-03-01), None
Sudbeck, E. et. al., Clinical Cancer Research, Jun. 1999, vol. 5, pp. 1569-1582.
Malaviya, R. et. al., The Journal of Biological Chemistry, Sep. 1999, vol. 274, No. 38, pp. 27028-27038.
Amir, S. et al., “An inhibitor of nitric oxide production, NG-nitro-L-arginine-methyl ester, improves survival in anaphylactic shock”.Eur. J. Pharmacol., vol. 203, No. 1, pp. 125-127 (Oct. 2, 1991).
Apgar, J., “Increased degranulation and phospholipase A2, C, and D activity in RBL cells stimulated through FcεR1 is due to spreading and not simply adhesion”,J. Cell. Sci., vol. 110, No. 6, pp. 771-780 (Mar. 1997).
Blank, U. et al., “Complete structure and expression in transfected cells of high affinity IgE receptor”,Nature, vol. 337, No. 6203, pp. 187-189 (Jan. 12, 1989).
Böhm, H-J, “The development of a simple empirical scoring function to estimate the binding constant for a protein-ligand complex of known three-dimensional structure”,J. Comput. Aided Mol. Des., vol. 8, No. 3, pp. 243-256 (Jun. 1994).
Buckley, R. et al., “Human severe combined immunodeficiency: Genetic, phenotypic, and functional diversity in one hundred eight infants”,J. Pediatr., vol. 130, No. 3, pp. 378-387 (Mar. 1997).
Chen, C-L., et al., “Pharmacokinetics and Biologic Activity of the Novel Mast Cell Inhibitor, 4-(3′-Hydroxyphenyl)-amino-6,7-dimethoxyquinazoline in Mice”,Pharmaceutical Research, vol. 16, No. 1, pp. 117-122 (Jan. 1999).
Costello, P. et al., “Critical role for the tyrosine kinase Syk in signalling through the high affinity IgE receptor of mast cells”,Oncogenevol. 13, No. 12, pp. 2595-2605 (Dec. 19, 1996).
Danial, N. et al., “Jak-STAT Signaling Induced by the v-abl Oncogene”,Science, vol. 269. No. 5232, pp. 1875-1877 (Sep. 29, 1995).
Darnell, Jr. J. et al., “Jak-STAT Pathways and Transcriptional Activation in Response to IFNs and Other Extracellular Signaling Proteins”,Science, vol. 264, pp. 1415-1421 (Jun. 3, 1994).
Deckert, M. et al., “Coordinated Regulation of the Tyrosine Phosphorylation of Cbl by Fyn and Syk Tyrosine Kinases”,J. Biol. Chem., vol. 273, No. 15, pp. 8867-8874 (Apr. 10, 1998).
Dvorak, A. et al., “Effects of Interleukin-3 With or Without the c-kitLigand, Stem Cell Factor, on the Survival and Cytoplasmic Granule Formation of Mouse Basophils and Mast Cells in Vitro”,Am. J. Pathol., vol. 144, No. 1, pp. 160-170 (Jan. 1994).
Endo, T. et al., “A new protein containing an SH2 domain that inhibits JAK kinases”,Nature, vol. 387, pp. 921-924 (Jun. 26, 1997).
Fusaki, N. et al., “Interaction between Sam68 and Src Family Tyrosine Kinases, Fyn and Lck, in T Cell Receptor Signaling”,J. Biol. Chem., vol. 272, No. 10, pp. 6214-6219 (Mar. 7, 1997).
Galli, S., “Seminars in Medicine of the Beth Israel Hospital, Boston: New Concepts About the Mast Cell”,New Eng. J. Med., vol. 328, No. 4, pp. 257-265 (Jan. 28, 1993).
Ghosh, S. et al., “α-Cyano-β-hydorxy-β-methyl-N-[4-(trifluoromethoxy)phenyl] Propenamide: An Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase with Potent Cytotoxic Activity against Breast Cancer Cells”,Clin. Cancer Res., vol. 4, No. 11, pp. 2657-2668 (Nov. 1998).
Goodman, P. et al., “Role of Tyrosine Kinases in Induction of the c-junProto-oncogene in Irradiated B-lineage Lymphoid Cells”,J. Biol. Chem., vol. 273, No. 28, pp. 17742-17748 (Jul. 10, 1998).
Gordon, J. et al., “Mast cells as a source of both preformed and immunologically inducible TNF-α/cachectin”,Nature, vol. 346, No. 6281, pp. 274-276 (Jul. 19, 1990).
Gurniak, C. et al., “Murine JAK3 Is Preferentially Expressed in Hematopoietic Tissues and Lymphocyte Precursor Cells”,Blood, vol. 87, No. 8, pp. 3151-3160 (Apr. 15, 1996).
Hamawy, M. et al., “Protein tyrosine phosphorylation as a mechanism of signalling in mast cells and basophils”,Cellular Signalling, vol. 7, No. 6, pp. 535-544 (Aug. 1995).
Hanissian, S. et al., “Jak3 Is Associated with CD40 and Is Critical for CD40 Induction of Gene Expression in B Cells”,Immunity, vol. 6, No. 4, pp. 379-387 (Apr. 1997).
Hirasawa, N. et al., “A Requirement for Syk in the Activation of the Microtubule-associated Protein Kinase/Phospholipase A2Pathway by FcεR1 Is Not Shared by a G Protein-coupled Receptor”,J. Biol. Chem., vol. 270, No. 18, pp. 10960-10967 (May 5, 1995).
Hoffman, S. et al., “JAK3 Maps to Human Chromosome 19p12 within a Cluster of Proto-oncogenes and Transcription Factors”,Genomics, vol. 43, No. 1, pp. 109-111 (Jul. 1, 1997).
Hogan, A. et al., “Markers of Mast Cell Degranulation”,METHODS: A Companion to Methods in Enzymology, vol. 13, No. 1, pp. 43-52 (Sep. 1997).
Hubbard, S. et al., “Crystal structure of the tyrosine kinase domain of the human insulin receptor”,Nature, vol. 372, No. 6508, pp. 746-754 (Dec. 1994).
Hubbard, S., “Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog”,The EMBO Journal, vol. 16, No. 18, pp. 5572-5581 (Sep. 15, 1997).
Ihle, J. et al., “Jaks and Stats in signaling by the cytokine receptor superfamily”,Trends in Genetics, vol. 11, No. 2, pp. 69-74 (Feb. 1995).
Ihle, J., “Janus kinases in cytokine signalling”,Phil. Trans. R. Soc. Lond. B, vol. 351, No. 1336, pp. 159-166 (Feb. 29, 1996).
Irani, A. et al., “Detection of MCTand MCTCTypes of Human Mast Cells by Immunohistochemistry Using New Monoclonal Anti-tryptase and Anti-chymase Antibodies”,J. Histochem. Cytochem., vol. 37, No. 7, pp. 1509-1515 (1989).
Johnston, J. et al., “Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2”,Nature, vol. 370, No. 6485, pp. 151-153 (Jul. 14, 1994).
Johnston, J. et al., Interleukins 2, 4, 7, and 15 Stimulate Tyrosine Phosphorylation of Insulin Receptor Substrates 1 and 2 in T Cells,J. Biol. Chem., vol. 270, No. 48, pp. 28527-28530 (Dec. 1, 1995).
Kumar, A. et al., “Structural organization and chromosomal mapping of JAK3 locus”,Oncogene, vol. 13, No. 9, pp. 2009-2014 (Nov. 7, 1996).
Lavens-Phillips, S. et al., “The effect of tyrosine kinase inhibitors in IgE-mediated histamine release from human lung mast cells and basophils”,Inflamm. Res., vol. 47, No. 3, pp. 137-143 (Mar. 1998).
Leonard, W., “STATs and cytokine specificity. Several STATs transduce signals and activate genes only in response to select cytokines —will all STATs prove so specific?”,Nature Medicine, vol. 2, No. 9, pp. 968-969 (Sep. 1996).
Levy, D., “The House that JAK/STAT Built”,Cytokine&Growth Factor Reviews, vol. 8, No. 1, pp. 81-90 (Mar. 1997).
Liu, F. et al., “Monoclonal Dinitrophenyl-specific Murine IgE Antibody: Preparation, Isolation, and Characterization”,J. Immunol., vol. 124, No. 6, pp. 2728-2737 (Jun. 1980).
Mahajan, S. et al., “Src Family Protein Tyrosine Kinases Induce Autoactivation of Bruton's Tyrosine Kinase”,Mol. Cell. Biol., vol. 15, No. 10, pp. 5304-53
Malavia Ravi
Sudbeck Elise A.
Uckun Fatih M.
Merchant & Gould P.C.
Parker Hughes Institute
Raymond Richard L.
LandOfFree
JAK-3 inhibitors for treating allergic disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with JAK-3 inhibitors for treating allergic disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and JAK-3 inhibitors for treating allergic disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3474525